Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 10pembrolizumab 7Cisplatin 7Oxaliplatin 4durvalumab 3Nivolumab 3130-nm albumin-bound paclitaxel 3fludarabine 2Specimen Handling 2Radiation 2Ipilimumab 2Drug Therapy 2Cyclophosphamide 2Capecitabine 2Biopsy 2tremelimumab 1trametinib 1tivozanib 1tislelizumab 1silmitasertib 1pertuzumab 1peposertib 1pemigatinib 1olutasidenib 1lenvatinib 1inositol trispyrophosphate 1futibatinib 1enasidenib 1devimistat 1derazantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cholangiocarcinoma × olutasidenib × Clear all
NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡